Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Cancer Therapy: Preclinical

Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma

Andrew C. Wood, Kateryna Krytska, Hannah T. Ryles, Nicole R. Infarinato, Renata Sano, Theodore D. Hansel, Lori S. Hart, Frederick J. King, Timothy R. Smith, Edward Ainscow, Kathryn B. Grandinetti, Tove Tuntland, Sunkyu Kim, Giordano Caponigro, You Qun He, Shiva Krupa, Nanxin Li, Jennifer L. Harris and Yaël P. Mossé
Andrew C. Wood
Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kateryna Krytska
Division of Oncology and Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hannah T. Ryles
Division of Oncology and Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicole R. Infarinato
Division of Oncology and Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Renata Sano
Division of Oncology and Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theodore D. Hansel
Division of Oncology and Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lori S. Hart
Division of Oncology and Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederick J. King
Genomics Institute of the Novartis Research Foundation, San Diego, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy R. Smith
Genomics Institute of the Novartis Research Foundation, San Diego, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward Ainscow
Genomics Institute of the Novartis Research Foundation, San Diego, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathryn B. Grandinetti
Genomics Institute of the Novartis Research Foundation, San Diego, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tove Tuntland
Genomics Institute of the Novartis Research Foundation, San Diego, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sunkyu Kim
Novartis Institutes of Biomedical Research, Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giordano Caponigro
Novartis Institutes of Biomedical Research, Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
You Qun He
Genomics Institute of the Novartis Research Foundation, San Diego, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shiva Krupa
Novartis Institutes of Biomedical Research, Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nanxin Li
Genomics Institute of the Novartis Research Foundation, San Diego, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer L. Harris
Genomics Institute of the Novartis Research Foundation, San Diego, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yaël P. Mossé
Division of Oncology and Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mosse@email.chop.edu
DOI: 10.1158/1078-0432.CCR-16-1114
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Purpose: Anaplastic lymphoma kinase (ALK) is the most frequently mutated oncogene in the pediatric cancer neuroblastoma. We performed an in vitro screen for synergistic drug combinations that target neuroblastomas with mutations in ALK to determine whether drug combinations could enhance antitumor efficacy.

Experimental Design: We screened combinations of eight molecularly targeted agents against 17 comprehensively characterized human neuroblastoma-derived cell lines. We investigated the combination of ceritinib and ribociclib on in vitro proliferation, cell cycle, viability, caspase activation, and the cyclin D/CDK4/CDK6/RB and pALK signaling networks in cell lines with representative ALK status. We performed in vivo trials in CB17 SCID mice bearing conventional and patient-derived xenograft models comparing ceritinib alone, ribociclib alone, and the combination, with plasma pharmacokinetics to evaluate for drug–drug interactions.

Results: The combination of ribociclib, a dual inhibitor of cyclin-dependent kinase (CDK) 4 and 6, and the ALK inhibitor ceritinib demonstrated higher cytotoxicity (P = 0.008) and synergy scores (P = 0.006) in cell lines with ALK mutations as compared with cell lines lacking mutations or alterations in ALK. Compared with either drug alone, combination therapy enhanced growth inhibition, cell-cycle arrest, and caspase-independent cell death. Combination therapy achieved complete regressions in neuroblastoma xenografts with ALK-F1174L and F1245C de novo resistance mutations and prevented the emergence of resistance. Murine ribociclib and ceritinib plasma concentrations were unaltered by combination therapy.

Conclusions: This preclinical combination drug screen with in vivo validation has provided the rationale for a first-in-children trial of combination ceritinib and ribociclib in a molecularly selected pediatric population. Clin Cancer Res; 1–13. ©2016 AACR.

Footnotes

  • Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

  • Received May 1, 2016.
  • Revision received November 29, 2016.
  • Accepted December 1, 2016.
  • ©2016 American Association for Cancer Research.
Next
Back to top

Published OnlineFirst March 13, 2017
doi: 10.1158/1078-0432.CCR-16-1114

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
Citation Tools
Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
Andrew C. Wood, Kateryna Krytska, Hannah T. Ryles, Nicole R. Infarinato, Renata Sano, Theodore D. Hansel, Lori S. Hart, Frederick J. King, Timothy R. Smith, Edward Ainscow, Kathryn B. Grandinetti, Tove Tuntland, Sunkyu Kim, Giordano Caponigro, You Qun He, Shiva Krupa, Nanxin Li, Jennifer L. Harris and Yaël P. Mossé
Clin Cancer Res March 13 2017 DOI: 10.1158/1078-0432.CCR-16-1114

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
Andrew C. Wood, Kateryna Krytska, Hannah T. Ryles, Nicole R. Infarinato, Renata Sano, Theodore D. Hansel, Lori S. Hart, Frederick J. King, Timothy R. Smith, Edward Ainscow, Kathryn B. Grandinetti, Tove Tuntland, Sunkyu Kim, Giordano Caponigro, You Qun He, Shiva Krupa, Nanxin Li, Jennifer L. Harris and Yaël P. Mossé
Clin Cancer Res March 13 2017 DOI: 10.1158/1078-0432.CCR-16-1114
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Enhanced Delivery of SN38-TOA NPs in NBs
  • Radiotherapy with IDO1/PD-1 Blockade Treats Advanced GBM
  • TCRs against MCV T-antigens
Show more Cancer Therapy: Preclinical
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement